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Skeletal myocytes are metabolically active and sus-
ceptible to insulin resistance and are thus implicated
in type 2 diabetes (T2D). This complex disease in-
volves systemic metabolic changes, and their eluci-
dation at the systems level requires genome-wide
data and biological networks. Genome-scale meta-
bolic models (GEMs) provide a network context for
the integration of high-throughput data. We gener-
ated myocyte-specific RNA-sequencing data and
investigated their correlation with proteome data.
These data were then used to reconstruct a compre-
hensive myocyte GEM. Next, we performed a
meta-analysis of six studies comparing muscle
transcription in T2D versus healthy subjects. Tran-
scriptional changes were mapped on the myocyte
GEM, revealing extensive transcriptional regulation
in T2D, particularly around pyruvate oxidation,
branched-chain amino acid catabolism, and tetrahy-
drofolate metabolism, connected through the down-
regulated dihydrolipoamide dehydrogenase. Strik-
ingly, the gene signature underlying this metabolic
regulation successfully classifies the disease state
of individual samples, suggesting that regulation of
these pathways is a ubiquitous feature of myocytes
in response to T2D.INTRODUCTION
Skeletal muscle is one of themost abundant tissues in the human
body, accounting for more than a third of our body weight (Lor-
enz and Campello, 2001), and is primarily composed of myo-cytes. Myocytes communicate with other tissues and organs,
such as liver and adipose, through secretion of myokines (e.g.,
myostatin, follistatin, and interleukins) (Pedersen and Febbraio,
2012), and the metabolism of myocytes has a major impact on
whole-body homeostasis. For instance, myocytes are respon-
sible for roughly 75% of the insulin-stimulated clearance of
glucose from the blood after a meal (Stump et al., 2006). As
such, myocytes are highly susceptible to insulin resistance,
and the dysfunction of myocyte metabolism is implicated in life-
style diseases such as obesity, metabolic syndrome, and type 2
diabetes (T2D), all of which are to date globally ubiquitous (Chen
et al., 2012).
These medical conditions are complex in their mode of action
even in the context of a single tissue, like muscle, in that alter-
ations at the systems level are required to contribute to their
progression. This complexity can be explored through the gener-
ation of state-of-the-art genome-wide ‘‘omics’’ data (e.g., tran-
scriptomics and proteomics) that provide a global and unbiased
insight into myocyte function, dysfunction, and metabolism.
Nevertheless, in order to gain as much knowledge as possible
from such data, it is essential to have informative scaffolds for
functional andmechanistic interpretation of genome-wide omics
data. In this context, genome-scale metabolic models (GEMs)
are useful representations of metabolism, and in the broad
area of human disease, they have successfully been used for
prediction and interpretation through simulation and data inte-
gration (Bordbar et al., 2014; Mardinoglu et al., 2013b; Va¨remo
et al., 2013b). GEMs are, simply put, a list of mass-balanced
metabolic reactions that are connected into a network structure
through their shared metabolites. Each reaction is assigned to a
specific compartment, e.g., the cytoplasm or mitochondria, and
associated to genes known to code for proteins involved in that
reaction. During the last decade, there has been an increased
development and application of human GEMs resulting in gener-
ation of several so-called context-specific GEMs. These GEMs
capture the active subset of metabolism present in a particularCell Reports 11, 921–933, May 12, 2015 ª2015 The Authors 921
Figure 1. Overview of the Workflow
(A) Myocyte-specific transcriptome data were generated using RNA-seq and compared to immunohistochemistry-based proteome data from the Human Protein
Atlas in order to evaluate the correlation and consistency between the transcript and protein levels.
(B) The proteome and transcriptome data were used to score the reactions in the generic human metabolic network HMR2 in order to evaluate the likelihood of a
metabolic reaction being present in myocytes. These scores were used as input to the tINIT algorithm, together with a list of metabolic tasks that the myocyte
GEM should be able to perform. The output of tINIT is a functional myocyte GEM that was manually curated, quality controlled, and compared to other existing
GEMs.
(C) The network topology of iMyocyte2419 was used to contextualize and interpret T2D transcriptome data from six different studies, comprising in total 153
subjects.context, such as a disease state (Agren et al., 2014) or specific
tissues and cell types (Bordbar et al., 2011; Mardinoglu et al.,
2013a, 2014).
Reconstructing context-specific (e.g., cell-type-specific)
GEMs requires high-quality genome-wide data and a compre-
hensive human metabolic network to use as a template. To
this end, we previously constructed the HumanMetabolic Reac-
tion (HMR) database (Agren et al., 2012), which has been contin-
uously updated (Mardinoglu et al., 2013a) and is currently in
version 2.0 (HMR2) (Mardinoglu et al., 2014). Reconstruction of
a context-specific GEM from the generic metabolic network is
a process of determining, for each metabolic reaction, whether
or not it should be present, while simultaneously maintaining a
connected network that represents a functioning model (Agren
et al., 2012). The evidence for the presence of a reaction can
be determined by experimentally measuring the existence of
its components, i.e., the relevant metabolites and enzymes,
and high-quality data with genome-wide coverage are therefore
essential for the reconstruction process. We have previously
constructed manually curated GEMs for the metabolically active
tissues liver (Mardinoglu et al., 2014) and adipose (Mardinoglu
et al., 2013a). Like skeletal muscle, these tissues are implicated
in complex human metabolic diseases such as T2D, and there is
a lot ofmetabolic interplay among the three tissues. It is therefore
of great interest to reconstruct the skeletal myocyte metabolism
in a comprehensive GEM.
Here, we generated cell-type-specific RNA-sequencing (RNA-
seq) data for human myocytes and studied the correlation of this922 Cell Reports 11, 921–933, May 12, 2015 ª2015 The Authorsdata with antibody-based immunohistochemistry for myocytes
from the Human Protein Atlas (Uhlen et al., 2010). These data
represent an extensive description of myocyte gene expression
at both the transcript and protein levels and enabled us to recon-
struct a comprehensive cell-type-specific skeletal myocyte
GEM. We next used the model to analyze and contextualize
T2D transcription data collected from six different studies
comprising in total 153 subjects. The meta-analysis of these
six studies provided a systems-level description of metabolic
regulation in T2D. Finally, we used the genes that underlie the
identified metabolic changes to classify individual T2D samples
from controls. An outline of the workflow is presented in Figure 1.
RESULTS
Cell-Type-Specific RNA-Seq Data for Human Skeletal
Myocytes
To quantify the skeletal myocyte-specific transcriptome, muscle
precursor cells were isolated from the vastus lateralis muscle of
three male and three female individuals (Table 1) and differenti-
ated into myotubes. These in vitro myocytes maintain genetic
and stable epigenetic components from their human donor, re-
sulting in a conservation of the in vivo phenotype in the in vitro
system (Broholm et al., 2012; Green et al., 2011; Scheele et al.,
2012). Thus, while cell lines rely on the fact that the gene expres-
sion in one single cell is representative of a cell population in a
given tissue or representative of a given human population, our
model system also takes biological variation into account. This,
Table 1. Characteristics of the Six Subjects
Female 1 Female 2 Female 3 Male 1 Male 2 Male 3
Age (years) 50 51 66 49 51 51
Body mass index (kg/m2) 23.0 24.0 24.8 23.7 23.9 24.4
Plasma glucose (mmol/l) 4.9 5.0 5.5 5.6 6.4 4.9
Plasma insulin (pmol/l) 25 17 36 26 24 20
HOMA-IR 0.47 0.38a 0.69 0.5 0.48 0.38
Plasma total cholesterol (mmol/l) 5.0 6.2 5.4 4.3 5.0 6.8
Plasma HDL cholesterol (mmol/l) 2.0 3.0 1.7 1.0 1.3 2.0
Plasma LDL cholesterol (mmol/l) 2.7 3.0 3.1 2.7 3.2 4.2
Plasma triglyceride (mmol/l) 1.16 0.72 0.97 1.20 1.38 1.40
Sequencing depth (M paired-end reads) 48.0 84.9 62.6 45.8 68.9 49.5
Phenotypic characteristics, selected plasma levels, and sequencing depth for the six samples.
aThe minimum allowed input (20 pmol/l) for plasma insulin was used for HOMA-IR calculation.along with the fact that the culture only contains myocytes, in
contrast to heterogeneous tissue biopsies, enables the recon-
struction and analysis of myocyte-specific metabolism.
Isolated myocyte mRNA was sequenced at an average depth
of 60 million paired-end reads per sample, and relative abun-
dances in the form of FPKM (fragments per kilobase per million
mapped reads) values were calculated for each protein-coding
gene. The transcriptomes of the six samples showed high pair-
wise correlations (Figure 2A), and the vast majority of expressed
genes (with FPKM >1) were expressed in all samples (Figure 2B).
We identified 35 differentially expressed genes between males
and females, including NDUFA4L2, COX7A1, CD36, GPR116,
and Il6, indicating a higher activity of lipid and energymetabolism
in female myocytes (see Supplemental Results and Table S1).
Correlation between Myocyte Transcriptome
and Proteome
The immunohistochemistry-based protein abundance data from
the Human Protein Atlas (HPA) version 12 (Uhlen et al., 2010)
contains protein abundance levels (not detected, low, medium,
or high) for 16,378 genes in skeletal myocytes. In HPA, the reli-
ability of the abundance level of a given protein is either ‘‘sup-
portive’’ or ‘‘uncertain,’’ depending on the extent and quality of
evidence, and currently, 12,260 genes, 75% of the genes
measured in skeletal myocytes, are associated with abundance
levels with uncertain reliability (Figure 2C).
A positive correlation betweenmRNA and protein abundances
has been reported (Lundberg et al., 2010; Nagaraj et al., 2011;
Schwanha¨usser et al., 2011), although transcript levels cannot
fully explain the variation of protein concentrations in a cell,
due to post-transcriptional events (Vogel and Marcotte, 2012).
However, mRNA abundances are generally believed to be
adequate for simply predicting protein presence/absence (Ram-
akrishnan et al., 2009).
We used the myocyte-specific RNA-seq data for evaluating if
the myocyte proteome and transcriptome are correlated. We
compared the FPKM-value distributions (median of the six sam-
ples) of genes with different protein abundance levels and sepa-
rated the supportive and uncertain data. For the uncertain
protein abundance levels, there was no clear difference betweenthe FPKM-value distributions of the non-detected and detected
(low, medium, or high) proteins in HPA, but more prominently, for
the more reliable supportive protein abundance levels, the de-
tected proteins generally had distinctively higher FPKM values
(Figure 2D), indicating a clear relation between expressed pro-
teins and high transcript levels.
Refining the Protein Abundance Scores Using
RNA-Seq Data
Since the observed difference in transcript levels between de-
tected (low, medium, or high) and non-detected proteins is not
apparent for the proteins with uncertain protein abundance
levels, a portion of these proteins has likely been assigned an
incorrect abundance level. To investigate this, we checked the
FPKM-value distribution specifically for proteins with abundance
levels that were updated, based on improved protein-level infor-
mation (according to the standards of HPA), from being non-de-
tected in previous versions of HPA to detected in the current
version. The FPKM-value distribution of these proteins showed
a similar pattern of higher values (Figure 2D), supporting the ra-
tionality behind an approach to use FPKM values to correct the
uncertain protein abundance levels.
An FPKM R 1 has previously been used as a threshold for
determining protein presence (Fagerberg et al., 2014; Heben-
streit et al., 2011). This was based on the observation of a
bimodal distribution of expression abundances that separated
genes into two groups, referred to as lowly expressed (LE) and
highly expressed (HE) genes (Hebenstreit et al., 2011). Our myo-
cyte RNA-seq data also showed this pattern, and importantly,
the FPKM values of the detected proteins with supportive reli-
ability (most likely expressed on a protein level) matched the
HE distribution (Figure 2E). For our data, the HE and LE group
were also divided at an FPKM value around 1, so this value
was selected as the cutoff.
We considered the HPA protein-level data as the primary
source of enzyme evidence but used the RNA-seq data to
reduce potential false negatives (as indicated in Figure 2C),
i.e., assigning the abundance level low (detected) to the
missing proteins in HPA and the uncertain non-detected pro-
teins, if their FPKM R 1. Based on this, 2,460 genes withCell Reports 11, 921–933, May 12, 2015 ª2015 The Authors 923
Figure 2. Comparison of Proteome and Transcriptome Data
(A) Pairwise Spearman correlations and scatterplots of log10(FPKM values), for the six subjects, show a high consistency of their transcriptomes.
(B) A majority of genes with an FPKM value larger than 1 are expressed in all six samples, showing a high consistency in whether or not a gene is expressed.
(C) The pie chart shows a summary of the coverage of protein-coding genes in the Human Protein Atlas (HPA). A majority of the genes are associated with protein
abundance levels with uncertain reliability, and more than 6,000 genes remain to be measured.
(D) The (median) FPKM-value distributions are displayed separately for the genes of the different HPA abundance groups. For the genes with supportive protein
abundance levels, there is a clear pattern of higher FPKM values for detected proteins (green) than non-detected proteins (red). This pattern is not apparent for the
genes with uncertain abundance levels, indicating that a portion of these are incorrectly scored. Indeed, genes that were incorrectly scored in previous HPA
versions but subsequently updated when new evidence was acquired according to the standards of HPA also show a pattern of higher FPKM values.
(E) The FPKM-value distribution of all genes show two peaks, representing lowly expressed (LE) genes and highly expressed (HE) genes. The HE genes have been
shown to be more likely to be translated into functional proteins. In line with this, the histogram of detected and supportive genes (in HPA) fits the HE part of the
density plot. The two peaks are divided at an FPKM of roughly 1, and this was chosen as a cutoff, so that non-detected genes (in HPA) with uncertain protein
abundance levels were updated to be detected, if their FPKM-value was larger than 1. The lowermost boxplot in (D) shows the FPKM values of these genes.
See also Table S2.uncertain non-detected protein abundance levels and
FPKM R 1 were relabeled as detected (their FPKM values
are summarized in the lowermost boxplot in Figure 2D). Addi-
tionally, 3,221 genes with protein-level information missing in
HPA and with FPKM R1 were also added as detected. Table
S2 gives a summary of the updated genes and their number
of associated reactions.
Reconstructing iMyocyte2419, a Comprehensive
Myocyte GEM
The updated protein abundance levels were used to score the
reactions in HMR2 so that a reaction received a positive score
if at least one associated enzyme was determined detected in
myocytes. During the reconstruction process, we also included
known functionality of the myocytes by defining a list of 247
metabolic functions (or tasks) that the myocyte GEM should be924 Cell Reports 11, 921–933, May 12, 2015 ª2015 The Authorsable to perform (Table S3), e.g., simulating uptake of fatty acids
and cholesterol from lipoproteins. Using the tINIT (task-driven
Integrative Network Inference for Tissues) algorithm (Agren
et al., 2012, 2014), which is part of the RAVEN toolbox (Agren
et al., 2013), a draft myocyte GEM was generated based on
the positive and essential reactions, while ensuring a connected
networkwhere all reactions could carry flux. Next, a relatively low
amount of reactions (22) were added so that the final model
could perform all the required tasks. Finally, relevant exchange
reactions were reintroduced and negative gene associations
were removed. The resulting skeletal myocyte GEM, iMyo-
cyte2419, consists of 5,590 reactions in eight different compart-
ments, 4,448 metabolites (2,396 unique), and 2,419 genes.
iMyocyte2419 can be downloaded in the systems biology
markup language (SBML) format from the repository of curated
models at http://www.metabolicatlas.org.
Figure 3. Comparison and Validation of the
Myocyte GEM
(A) The myocyte GEM, iMycoyte2419, was
compared to two previously published, yet
smaller-scale, muscle GEMs. The barplot shows
the number of genes and reactions in each model.
(B) The Venn diagram shows the gene overlap
among the three models. The pie charts show the
gene scores (based on the RNA-seq and HPA
data) for the indicated genes. As can be seen, the
majority of the excluded genes in iMyocyte2419
have negative scores (non-detected), whereas
only 78 out of 2,419 genes in iMyocyte2419 have a
negative score.
See also Tables S4 and S5 for more details.iMyocyte2419 Has Increased Metabolic Coverage
Compared to Previous Models
Two small-scale GEMs for skeletal muscle, based on tissue-
level omics data, have previously been published (Bordbar
et al., 2011; Wang et al., 2012). In terms of numbers of reac-
tions and genes, both of these GEMs are significantly smaller
than iMyocyte2419 (Figure 3A). Nevertheless, it is interesting
to compare the overlap of the three GEMs (Figure 3B). In
terms of gene content, 82% of the Bordbar GEM and 70%
of the Wang GEM are encompassed by iMyocyte2419. There
are 286 genes (Table S4) in the muscle GEMs that are
excluded from iMyocyte2419, and the reason is that the ma-
jority of these have negative scores (not detected) based on
the RNA-seq and proteomics data. Of the 11 genes with pos-
itive scores (detected), 4 are not included in HMR2, 4 were
discarded during reconstruction in favor of preserving connec-
tivity of the network, and 3 are actually included in iMyo-
cyte2419 but under different Ensembl IDs. In contrast, the
majority of the genes included in iMyocyte2419 are positively
scored, whereas only 78 out of 2,419 genes have a negative
score.
Although it is expected to have a small number of negatively
scored genes in the final model, due to the constraints that are
put to ensure a connected and functional network, we investi-
gated why these genes were included. Out of the 78 genes with
negative scores in iMyocyte2419, 58 are detected at the tran-
script level (FPKM value above 0) and 38 of these have
FPKM values above 1 (Table S5). The 78 genes are associated
with 292 reactions (5.2% of total reactions) that were not asso-
ciated with any other positive genes. These reactions were
required to be included in iMyocyte2419 either because they
were part of pathways where several other proteins had a pos-
itive score (connectivity) or to successfully simulate all of the
required metabolic tasks (functionality). Since the myocyte
GEM provides a network-based representation of myocyte
metabolism, the 78 genes with a negative score in HPA may
actually be false negatives. To investigate this, we reevaluated
the existing protein-level evidence in HPA for the 78 negative
genes and, based on this, it was determined that 14 genes
(Table S5) would be updated in HPA (version 13) as being de-
tected in myocytes. This shows how the contextual analysis of
proteins, provided by the GEM reconstruction, can assist in
data curation.Meta-Analysis of T2D Muscle Gene Expression
The topology of iMyocyte2419 provides a scaffold for interpret-
ing high-throughput data in the context of myocyte metabolism.
To establish a consensus result of the metabolic changes that
occur in skeletal muscle of T2D subjects, we queried the Gene
Expression Omnibus (GEO) data repository (Edgar et al., 2002)
and ArrayExpress (Rustici et al., 2013) for relevant microarray
datasets. This resulted in eight datasets that fitted our criteria
(see Experimental Procedures for details).
Meta-analysis is used to combine multiple studies with similar
hypotheses into one unified result. Ramasamy et al. (2008) stud-
ied the key issues in microarray meta-analysis and recommen-
ded themethod proposed by Choi et al. (Choi et al., 2003), which
we used here. Briefly, a Z score is calculated for each gene, and
significant genes altered in T2Dmuscle can then be identified by
selecting genes with absolute Z scores larger than a given
threshold.
First, we calculated gene-wise Z scores for the eight individual
datasets in order to calculate the Pearson correlation between
each possible pair of studies. Surprisingly, even though the data-
sets were selected to include baseline skeletal muscle samples
from people with T2D and healthy control subjects, two datasets
(Gallagher and Wu) clearly stood out by showing negative corre-
lation with themajority of the remaining datasets (Figure 4A). This
pattern could not, as far as we could assess, be explained by the
subject characteristics (e.g., body mass index, age, or fasting
glucose levels), microarray platforms, or muscle types used in
these datasets (Table S6). We also checked for possible sample
contamination of immune cells by using the R-package ESTI-
MATE (Yoshihara et al., 2013), but again, no pattern was found
that could explain the negative correlation of these two datasets
with the rest (Figure S1). In order to perform a meta-analysis of a
set of studies that represent a consistent gene expression
phenotype, we decided to focus on the bigger group of six
studies (Table 2) and exclude the Gallagher and Wu datasets
from our meta-analysis. As it turned out, the meta-analysis of
these six studies, comprising in total 86 T2D samples and 67
controls, recapitulated several known biological processes
attributed to T2D (as described below), supporting the selection
of these studies for further analysis.
Onemajor advantagewithmeta-analysis is the increase in sta-
tistical power as the sample size increases, and this can be illus-
trated by the integrated discovery rate (IDR) (Choi et al., 2003),Cell Reports 11, 921–933, May 12, 2015 ª2015 The Authors 925
Figure 4. Meta-Analysis of Type 2 Diabetes Gene Expression
(A) A heatmap of pairwise Pearson correlations, based on the genes with jZj > 1 in both compared studies. The Gallagher and Wu datasets showed a negative
correlation with most of the remaining studies and cluster separately in the hierarchical clustering. In order to analyze an overall consistent phenotype, these two
studies were not considered in the downstream analysis. See also Figure S1 and Tables 2 and S6 for details about the studies.
(B) The plot shows the fraction of significant genes, in the meta-analysis, that were not significant in any individual study, for different Z score cutoffs. The dashed
lines similarly show the fraction of non-significant genes, in the meta-analysis, that were found significant in at least one of the individual studies. At a Z score
cutoff around 3, in principle, no genes are lost from the individual studies, whereas the increased statistical power of themeta-analysis identifies a large fraction of
significant genes that were not possible to detect in the individual studies.
(C) The plot shows the number of significant genes, in the meta-analysis and in each individual study, at different Z score cutoffs, showing the power of the meta-
analysis.
(D) A gene-set analysis (GSA) of the meta-analysis results, using the pathways of iMyocyte2419 as gene sets, show pathways significantly affected by tran-
scriptional regulation. The q-values (FDR-adjusted p values) are medians from the GSA methods used in the consensus GSA. In T2D, all pathways are either
distinctly downregulated, or are affected by a subset of downregulated genes.
See also Figure S2 for the GO-term analysis and Tables S7, S8, and S9 for the meta-analysis Z scores and the complete GSA results.i.e., the fraction of significant genes detected in the meta-anal-
ysis (by integrating studies) that is not detected in any of the in-
dividual datasets. Figure 4B shows the IDR for upregulated and
downregulated genes, as well as the fraction of non-significant
genes in the meta-analysis that were significant in any of the in-
dividual datasets, i.e., the potential loss of information, study-
specific effects, or false positives in the individual datasets. At
a Z score threshold of 3, close to 50% of the significant genes
in the meta-analysis would not be identified by analyzing any of
the individual datasets and practically no significant genes iden-
tified by any of the individual datasets were lost in themeta-anal-
ysis. In Figure 4C, the number of significant genes at different Z926 Cell Reports 11, 921–933, May 12, 2015 ª2015 The Authorsscore thresholds shows that the meta-analysis always detected
more genes than any of the individual studies.
Integrating the Meta-Analysis Results with
iMyocyte2419 Reveals Pathways Implicated in T2D
We used the gene-reaction associations to investigate if any
specific metabolic processes were significantly affected by
T2D gene expression. This was done through consensus gene-
set analysis (GSA) (Va¨remo et al., 2013a) with the meta-analysis
gene-wise Z scores as input data (Table S7) and the iMyo-
cyte2419 pathways as gene sets. Figure 4D shows themetabolic
pathways most significantly affected by differential gene
Table 2. Summary of the Microarray Datasets Used in the Meta-Analysis
Author T2D NGT Platform Genes Muscle Type Dataset ID PubMed ID
van Tienen et al. (2012) 10 12 HG-U133 Plus 2 20899 vastus lateralis GSE19420 22802091
Sears et al. (2009) 51 18 HG-U133 Plus 2 20899 vastus lateralis GSE13070 19841271
Pihlajama¨ki et al. (2011) 7 10 HG-U133 Plus 2 20899 rectus abdominis GSE22435 21803291
Jin et al. (2011) 10 15 HG-U133 Plus 2 20899 vastus lateralis GSE25462 21393865
Patti et al. (2003) 5 10 Hu6800 6060 vastus lateralis GSE21340 12832613
Chibalin et al. (2008) 3 2 Hu6800 6060 vastus lateralis E-MEXP-1270 18267070
T2D, number of type 2 diabetes samples; NGT, number of normal glucose-tolerant (control) samples; platform, Affymetrix microarray type; genes,
number of unique Ensembl gene IDs; muscle type, the origin of the biopsy; dataset ID, GEO accession number (except for the Chibalin dataset, which
comes from ArrayExpress).expression in T2D, all showing patterns of downregulation.
These include several processes suggested to be implicated in
T2D, such as oxidative phosphorylation, b-oxidation, tricarbox-
ylic acid cycle, glycolysis, and branched-chain amino acid
(BCAA) (valine, leucine, and isoleucine) metabolism (Abdul-
Ghani andDeFronzo, 2010; Lynch andAdams, 2014; Szendroedi
et al., 2012). Additionally, other less studied gene sets also
appear to be affected by transcriptional downregulation, namely
omega-6 fatty acid metabolism, vitamin E metabolism, nucleo-
tide metabolism, and cysteine and methionine metabolism.
In a similar manner, we used Gene Ontology (GO) terms as
gene sets, and this also pointed at regulation of metabolism, in
particular downregulation of genes coding for proteins acting
in the mitochondria, respiratory electron transport chain, oxido-
reductase activity, pyruvate metabolism, tricarboxylic acid cy-
cle, glucose metabolic process, and BCAA catabolic process
(Figure S2). Additionally, GO terms related to RNA splicing
(RNA helicase activity, RNA splicing, and mRNA processing)
were enriched by downregulated genes. A decreased expres-
sion of splicing factors in muscle of obese subjects has previ-
ously been reported by one of the studies included in the
meta-analysis (Pihlajama¨ki et al., 2011), and interestingly, this
signature is recapitulated also when taking all six studies into ac-
count. Finally, the GO-term analysis also revealed upregulation
of several immune-related processes, which is in line with the ev-
idence of inflammation being associated with the development
of T2D (Donath and Shoelson, 2011). The complete pathway
and GO-term GSA results are presented in Tables S8 and S9.
Topology-Based Analysis of the Meta-Analysis Results
Using iMyocyte2419
We next used the transcriptional data to identify reporter metab-
olites (Patil and Nielsen, 2005), which are metabolite gene sets
defined by the gene-reaction associations provided by iMyo-
cyte2419, so that for a given metabolite, a gene set consists of
all genes associated with reactions in which the metabolite is
participating. Consensus GSA was performed (complete results
are shown in Table S10), and the GSA visualization tool Kiwi was
used to process the results in order to highlight the most signif-
icant metabolites and their interconnectivity in the myocyte
metabolic network. In order to demonstrate the value of a myo-
cyte-specific GEM, we also performed the same analysis using
the generic human metabolic network, HMR2, which yielded
similar, but not identical, results (Figure S3). The two resultshave a Pearson correlation of 0.89 (based on the non-directional
median adjusted p values). This difference is due to the changes
made to the gene-metabolite edges to reflect the myocyte-spe-
cific metabolic topology, and this shows the value of cell-type-
specific models for integrative analysis.
As can be seen in the network plot (Figure 5A), most of the
implicated metabolites are mitochondrial (marked with [m]) and
affected by transcriptional downregulation (blue nodes) in T2D.
In addition to the general downregulation of mitochondrial pro-
cesses, the network plot is recapitulating on amore detailed level
some of the implicated parts of metabolism that were identified
in the pathway and GO-term analyses. The mitochondrial import
of pyruvate and its conversion to acetyl-coenzyme A (acetyl-
CoA) is affected by transcriptional downregulation indicated by
the reporter metabolites: pyruvate, CO2, S-acetyldihydrolipoa-
mide, lipoamide, and dihydrolipoamide. The underlying genes
associated with the reporter metabolites are displayed in Fig-
ure 5B, which illustrates significant downregulation of the mito-
chondrial pyruvate carrier MPC2, as well as PDHB, DLAT, and
DLD (all taking part in pyruvate oxidation). There is also an
apparent reduction of TCA cycle activity, shown by the reporter
metabolites fumarate, succinyl-coenzyme A (succinyl-CoA),
CO2, and FAD, as well as FADH2, H
+, NADH, and NAD+ (high-de-
gree metabolites that were excluded from the plot to preserve
readability).
In line with the observed downregulation of BCAAmetabolism
in the pathway andGO-term analysis, the reporter metabolites 3-
methylcrotonyl-coenzyme A, 2-methyl-3-oxopropanoate, dihy-
drolipoamide, lipoamide, and succinyl-CoA, intermediates of
BCAA degradation, are all surrounded by downregulated genes.
In particular, dihydrolipoamide dehydrogenase (DLD) is part of
the branched-chain alpha-keto acid dehydrogenase complex
(BCKDC), 3-methylcrotonyl-CoA carboxylase (MCCC1) is cata-
lyzing a key step in leucine degradation, short/branched chain
specific acyl-CoA dehydrogenase (ACADSB) is catalyzing an in-
termediate step in valine and isoleucine catabolism, and the
aldehyde dehydrogenase ALDH3A2 and methylmalonyl CoA
mutase (MUT) are catalyzing some of the last steps of the break-
down of valine and isoleucine to form succinyl-CoA.
The reporter metabolite 5,10-methenyl-THF is an intermediate
in folate one-carbon metabolism. It is one of several tetrahydro-
folate (THF) derivatives (also including 10-formyl-THF, 5,10-
methylene-THF, and 5-methyl-THF), which act as one-carbon
group donors in nucleotide synthesis, methionine synthesis,Cell Reports 11, 921–933, May 12, 2015 ª2015 The Authors 927
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purine synthesis, and DNAmethylation. Interestingly, two genes,
MTHFD1 and FTCD, are both associated with this metabolite but
are significantly regulated in different directions. The cytosolic
methylenetetrahydrofolate dehydrogenase (MTHFD1) is signifi-
cantly downregulated in T2D and is catalyzing the interconver-
sions of 5,10-methylene-THF, 5,10-methenyl-THF, and 10-
formyl-THF. Formimidoyltransferase cyclodeaminase (FTCD),
on the other hand, is significantly upregulated and functions to
contribute with one-carbon units from histidine degradation to
the folate pool.
Interestingly, the emergent downregulation surrounding the
lipoylproteins and lipoamides connects several of the implicated
parts of metabolism identified above, as they play an important
role in pyruvate, BCAA, and THF metabolism. The key enzyme
that is connecting these parts (as can be identified by the heat-
map in Figure 5B) is the transcriptionally downregulated DLD,
which is located in themitochondrial matrix, where it is a compo-
nent of the pyruvate dehydrogenase complex, the branched-
chain alpha-keto acid dehydrogenase complex, and the glycine
decarboxylase complex.
Finally, a separate subnetwork affected by transcriptional
regulation, which emerges from the reporter metabolite analysis,
is that of glyceraldehyde 3-phosphate (GAP), dihydroxyacetone
phosphate (DHAP), and sn-glycerol-3-phosphate. In particular,
GAP is the most statistically significant reporter metabolite, con-
nected to increased transcriptional activity, driven by the signif-
icantly upregulated genes transketolase (TKT), aldolase A and B
(ALDOA and ALDOB), and GAP dehydrogenase (GAPDH). Also
glycerol-3-phosphate dehydrogenase 1 (GPD1), connected to
DHAP and sn-glycerol-3-phosphate, is upregulated, but there
is also an influence of downregulated genes (DERA, GNPAT,
and GPD1L). In summary, this points toward an active transcrip-
tional regulation around the branch point of glycolysis, the
pentose phosphate pathway and lipid biosynthesis, in T2D skel-
etal muscle.
The Identified Metabolic Signatures Have the Power
to Classify T2D Samples
The subnetwork of reporter metabolites establish a metabolic
signature of T2D in muscle, across six different studies. In order
to determine if this signature was prominent enough to be recog-
nized at the level of individual subjects, we performed a sample
classification approach. To do this, we selected the most signif-
icant (p < 1e-5) genes among the ones connected to the reporterFigure 5. Metabolic Subnetworks Implicated in Type 2 Diabetes
(A) Using the tool Kiwi, the network of significant reporter metabolites was produc
apart in themetabolite-metabolite network (extracted from iMyocyte2419), and th
to avoid too unspecific connections, metabolite nodes with a degree above 73
metabolite-metabolite distances. The node size corresponds to the gene-set (rep
captures the general direction of change. See also Table S10 for the complete re
while using HMR2.
(B) The heatmap shows the significance and direction of regulation of the genes
(C) Themost significant genes, underlying themetabolic subnetwork (marked in re
individual samples, using a random forest model. The performance of the classi
curve for each study of the meta-analysis. See also Table S11.
(D) The area under the ROC curve (AUC) was calculated 100 times for each study b
to the AUC scores of classification based on random or randommetabolic genes (
the AUC scores from random genes, show that the metabolic signature shown imetabolites (marked in red in Figure 5B). These 12 genes are
associated with 20 out of 25metabolite gene sets, thus generally
representing the affected identified metabolic subnetwork.
First, we investigated to what extent each gene influenced the
myocyte function by blocking the associated reactions in iMyo-
cyte2419 and testing what metabolic tasks (Table S3) the GEM
would fail to carry out. The 12 genes disrupted in total 105 of
the 247 metabolic tasks (Table S11), and the biggest effect in
terms of number of failed tasks was observed for ACADL and
HADH, both disrupting 55 tasks.
Next, for each study, the disease state (healthy or diabetic) of
each sample was predicted based on a random forest model
trained on the expression values of the 12 genes in the remain-
ing samples. The performance of the classification is shown by
receiver-operating characteristic (ROC) curves for the six
studies (Figure 5C). The area under the ROC curve (AUC) is
shown in Figure 5D, while repeating the classification 100 times
for each study, and can be compared to the AUC scores of us-
ing random genes (orange) or random metabolic genes (red) as
classifiers. The AUC scores are larger than random in all six da-
tasets, illustrating the relevance of these 12 representative
genes on a sample-wise level, across several studies. This sug-
gests that the expression patterns of these genes and the cor-
responding effects in metabolism are a ubiquitous feature of
T2D in muscle.
DISCUSSION
Here, we reconstructed the skeletal myocyte metabolism and by
that provide a comprehensive myocyte GEM. This was in large
part enabled by the high-quality proteome data from HPA and
the RNA-seq data generated in this study, together providing
an extensive description of myocyte-specific gene expression.
Human genome-wide data are often collected from tissue sam-
ples, but in order to study the myocyte metabolism, our goal was
to make a cell-type-specific, rather than tissue-specific, GEM. In
this context, the myocyte-specific RNA-seq data were invalu-
able for the reconstruction process. The use of in vitro myocytes
could arguably be a step away from in vivo biology; however,
data show that these cells are able to recapitulate known pheno-
types of their donors (Broholm et al., 2012; Green et al., 2011;
Scheele et al., 2012), including known differences between
males and females, such as higher lipid and energy metabolism
in females, as shown here.ed. An edge between twometabolites means that they are less than three steps
e thickest edges connect themetabolites that are closest to each other. In order
(mainly co-factors) were removed from the network prior to calculating the
orter metabolite) significance (median of non-directional p value), and the color
porter metabolite results and Figure S3 for a comparison to the same analysis
connected to the metabolites in (A).
d in the heatmap) were used to classify the disease state (healthy or diabetic) of
fication is shown by (a representative) receiver-operating characteristic (ROC)
y repeating the random forest classification (green bars) and can be compared
yellow and red bars). The high AUC scores, and the fact that they are larger than
n (A) is relevant also on the level of individual T2D subjects.
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The myocyte GEM, iMyocyte2419, is a valuable resource that
can be used in future research on muscle metabolism, providing
a scaffold for data integration and support for analyzing genome-
wide data, as demonstrated in this study. Furthermore, the GEM
can be used for simulation of muscle metabolism, and there is an
increasing interest in studying the metabolic interactions be-
tween cells and tissues and the implication this has on blood
metabolite levels and whole-body metabolism. An approach to
accomplish this task is to connect multiple GEMs (Bordbar
et al., 2011), which requires a proper simulation framework and
high-quality cell-type-specific GEMs. The myocyte GEM,
together with our previous published models of hepatocyte
and adipocyte metabolism (Mardinoglu et al., 2013a, 2014), con-
stitutes an essential step in this direction.
The value of our reconstructed GEM for analysis of transcrip-
tion data was here clearly demonstrated by the identification of
metabolic anomalies associated with T2D, some consistent
with earlier findings but several not reported before. A set of
genes associated with oxidative phosphorylation have previ-
ously been shown to be downregulated in human diabetic mus-
cle tissue (Mootha et al., 2003), and this, together with mitochon-
drial dysfunction, has repeatedly been reported as one of the
signatures of T2D muscle (Szendroedi et al., 2012). Conversely,
other studies report a normal mitochondrial function in T2D
(Boushel et al., 2007) and no difference in oxidative phosphory-
lation (De Feyter et al., 2008) or the expression of associated
genes (Frederiksen et al., 2008). The Gallagher study (Gallagher
et al., 2010), which we briefly considered here, found no differ-
ence in expression of genes in the oxidative phosphorylation
gene set, as opposed to Mootha et al. (2003), and speculated
that this may be because the subjects in the latter study were
exposed to insulin prior to biopsy sampling, suggesting that a
reduced oxidative phosphorylation could be explained by a dis-
similar acute insulin response rather than a baseline difference.
In order to not be confounded by data from a single study, we
performed a meta-analysis in order to establish a consistent
result across multiple datasets. This analysis covered T2D
gene expression in human muscle from six studies covering
153 subjects, and the findings reported here are thus supported
on a wider base. Following the speculations of Gallagher et al.
(2010), during the selection of the studies for the meta-analysis,
we excluded all studies where subjects had been exposed to any
insulin stimuli (e.g., a hyperinsulinemic-euglycemic clamp) prior
to biopsy sampling. Regardless, the results from our pathway
analysis showed a significant downregulation of oxidative phos-
phorylation. Thus, at least across the six studies of the meta-
analysis, there is an association between T2D and reduced
expression of oxidative phosphorylation genes, although it still
remains to be investigated if this is a cause or an effect of T2D.
The Gallagher study, which reported no difference in oxidative
phosphorylation between diabetics and controls, was excluded
from the main meta-analysis (together with the Wu dataset) due
to negative correlation with the other six studies, but while
running our analyses, no pathways were found to be significantly
changed (at q < 0.05) in a separate meta-analysis of these two
datasets. Furthermore, when including these two datasets in
the meta-analysis, oxidative phosphorylation was still found
significantly downregulated.930 Cell Reports 11, 921–933, May 12, 2015 ª2015 The AuthorsThe topology of iMyocyte2419 gave us a unique opportunity to
further dissect the meta-analysis results to the level of individual
metabolites in a network-based approach. This analysis re-
vealed connected metabolic subnetworks affected by T2D tran-
scriptional regulation, in particular around pyruvate oxidation,
BCAA catabolism, and tetrahydrofolate metabolism. These re-
sults were found to be very robust markers of T2D, and based
on the underlying top significantly differentially expressed genes,
we were able to classify the disease state of individual samples,
yielding high AUC scores (Figure 5D).
The downregulation surrounding 5,10-methenyl-THF has, to
our knowledge, not been reported before in human diabetic skel-
etal muscle. Interestingly, two of the pathways, methionine and
nucleotide metabolism, that THF-derivatives are precursors for
were also identified as affected by transcriptional downregula-
tion in the pathway analysis. There is also an influence of both
upregulation and downregulation around 5,10-methenyl-THF.
The downregulated MTHFD1 suggests a decreased activity
around interconversion of THF intermediates, whereas there is
an upregulation of FTCD that could indicate a contribution into
THF metabolism from histidine catabolism. Plasma histidine
has been reported to be associated with positive effects on dia-
betes, such as reduced blood glucose levels (Stanca´kova´ et al.,
2012), triglycerides, and proinflammatory cytokines (Lee et al.,
2005). Histidine has also been shown to reduce gluconeogenesis
in liver (possibly by activating IL6/STAT3 signaling, but without
increasing insulin levels), and it was therefore suggested as a
candidate target for T2D treatment (Kimura et al., 2013). Specu-
latively, increased histidine catabolism in muscle could reduce
plasma histidine, limiting its reported positive effects on T2D.
When we specifically checked the expression of genes in our
meta-analysis belonging to the histidine degradation pathway,
we did coincidently find an upregulation (p < 0.07) of both histi-
dine ammonia-lyase (HAL) and urocanate hydratase 1
(UROC1).UROC1 has previously been found to be demethylated
in the placenta of rats with gestational diabetes (Petropoulos
et al., 2014).
Increased plasma levels of BCAAs have been associated with
T2D, and it has been hypothesized that BCAAs can promote in-
sulin resistance either by activating mTORC1 signaling, which in
turn can lead to inhibition of insulin signaling, or by leading to
toxic accumulation of BCAA metabolites through disruptive
BCAA metabolism, which could lead to mitochondrial dysfunc-
tion (Lynch and Adams, 2014). In line with our results, a
decreased expression of BCAA catabolism in muscle has been
reported before (Lefort et al., 2010). It has also been shown
that insulin lowers plasma BCAA levels and increases the
expression in liver of DLD and 3-methylcrotonyl-CoA carbox-
ylase (Shin et al., 2014), both genes that we identified with oppo-
site patterns in the meta-analysis, i.e., downregulated in diabetic
muscle. These authors also reported that insulin lowered liver
levels of 3-methylcrotonyl-CoA, an intermediate in BCAA catab-
olism and a metabolite that was identified in our analysis as a re-
porter metabolite in diabetic muscle. Interestingly, our network
analysis also identified lipoamide-containing proteins, con-
nected to the downregulation of DLD, as contributors not only
to decreased BCAA catabolism but also to the downregulation
that we observed around pyruvate and THF metabolism. DLD
is catalyzing the reaction of dihydrolipoamide to lipoamide,
which is needed as an intermediate step in the carboxylation of
pyruvate, branched-chain alpha-keto acids (which is a step in
BCAA degradation), and glycine (at the same time forming
5,10-methylene-THF from THF).
In conclusion, our extensive analysis, using multiple transcrip-
tome datasets, comprehensive metabolic modeling, consensus
GSA, and network topology analysis, provided a holistic insight
into the metabolic state of type 2 diabetic human muscle. The
identified metabolic signature of T2D was confirmed by classifi-
cation of the sample disease states, across multiple cohorts,
based on gene expression patterns. Finally, the myocyte-spe-
cific GEM iMyocyte2419, which was reconstructed based on
myocyte-specific transcriptome and proteome data, provides
a valuable and useful resource for future studies.
EXPERIMENTAL PROCEDURES
Subject Selection and Characteristics
Six normal glucose tolerant and non-obese males and females (aged 49–66
years, body mass index 23.0–24.8 kg/m2) were selected from a previous
cohort (Green et al., 2011; Møller et al., 2014). All participants gave written
informed consent before inclusion, and the study was performed according
to the Declaration of Helsinki and approved by The Regional Committee on
Biomedical Research Ethics in Denmark (KF 01-141/04). HOMA-IR values
were calculated using the HOMA2 Calculator 2.2.3 (https://www.dtu.ox.ac.
uk/homacalculator/).
Culturing of Myocytes and Sampling of RNA
Muscle precursor cells (satellite cells) were isolated from human skeletal mus-
cle biopsy specimens obtained from the vastus lateralis muscle using a biopsy
needle with suction (Bergstro¨m, 1975) as described in detail previously (Green
et al., 2011). Isolated satellite cells were cultured and fully differentiated (see
Supplemental Experimental Procedures). Total RNA was extracted using Tri-
zol (Life Sciences) according to the manufacturer’s instructions. Frozen sam-
ples were shipped to the sequencing facility where they were purified by
poly(A) enrichment using Illumina TruSeq RNA.
RNA-Seq and Data Analysis
The raw sequence reads were trimmed from adaptor sequences and aligned
to the human genome using STAR (Dobin et al., 2013). FPKM values and
gene counts were calculated using Cufflinks (Trapnell et al., 2010) and
HTSeq-count (Anders et al., 2015). Differential expression was assessed using
edgeR (Robinson et al., 2010). See Supplemental Experimental Procedures for
more details.
Reconstructing the Myocyte GEM
To reconstruct the myocyte GEM, the gene scores acquired from the Human
Protein Atlas and the RNA-seq data were used by the tINIT algorithm, together
with HMR2 as reference model and the metabolic tasks defined in Table S3.
See further details in Supplemental Experimental Procedures.
Meta-Analysis
The GEO database and ArrayExpress were queried for datasets that con-
tained subjects with T2D or insulin resistance, and that had not been given
any stimuli (such as insulin or drug) prior to biopsy sampling, according to
the description given in the corresponding publications, which resulted in
eight datasets. Six of these (see Table 2) were used in the final analysis,
and two (GEO accession numbers GSE22309 and GSE18732) were excluded
due to negative correlation with the others. The datasets were preprocessed
(see Supplemental Experimental Procedures) and the meta-analysis was car-
ried out according to Choi et al. (2003), and as implemented in the Bio-
conductor R package GeneMeta, using a random-effects model, yielding
one Z score for each gene.Pathway and GO-Term Analysis
The pathway and GO-term analyses were performed using the consensus
GSA approach implemented in the Bioconductor R package piano (Va¨remo
et al., 2013a). Each GSA method generates its own gene-set p values based
on gene permutation. The consensus approach then yields a consensus score
for each gene set, and the median p value for each gene set is reported (see
details in Supplemental Experimental Procedures). The heatmap in Figure 4D
shows log10(median of false discovery rate [FDR]-adjusted p values) of the
pathways with a median adjusted p < 0.005 (in at least one of the directionality
classes), and the heatmap in Figure S2 shows log10(median of FDR-
adjusted p values) of the GO terms with a median adjusted p < 0.05 (in the
non-directional class).
Reporter Metabolite Analysis
Reporter metabolite analysis was performed using piano, as described above,
and the metabolite-reaction-gene associations of iMyocyte2419 (and HMR2)
to create the metabolite gene sets. The Python package Kiwi (Va¨remo et al.,
2014) was used to make the network plot (Figure 5A). For this, the metabo-
lite-metabolite network was reduced to metabolites with degrees % 73
(removing mainly co-factors). The p value cutoff was set to 0.001, and the
shortest path-length (SPL) cutoff was set to 3. The network plot layout was
manually adjusted in Cytoscape.
Random Forest Classification
The random forest classificationwas carried out, using the R package random-
Forest, by leave-one-out cross-validation, so that the disease state of each
sample was predicted using a model based on gene expression data from
the remaining samples. See Supplemental Experimental Procedures for
further details.
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